Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ABBV

Champion - 10+ consecutive years of dividend increases

Max Ratio

8.77

5Y Dividend Growth

45.00 %

Consecutive Years

11 years

5Y Average Payout Ratio

161.73 %
Forward Annual Dividend Yield 3.44 %
Consecutive Years 11
Forward Annual Dividend 6.56 USD
Consistent Years 11
Dividend CAGR 3Y 6.04 %
Continuous Dividends
Dividend CAGR 5Y 7.69 %
Payout Ratio TTM 199.14 %
Dividend CAGR 10Y 14.08 %
Ex Dividend Date 15.07.2025

AbbVie Inc

ABBV
Current price
190.58 USD +3.66 USD (+1.96%)
Last closed 186.39 USD
ISIN US00287Y1091
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 329 239 298 048 USD
Yield for 12 month +11.36 %
1Y
3Y
5Y
10Y
15Y
ABBV
21.11.2021 - 28.11.2021

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

209.12 USD

P/E Ratio

79.31

Dividend Yield

3.44 %

Financials ABBV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+56 334 000 000 USD

Last Year

+54 318 000 000 USD

Current Quarter

+13 343 000 000 USD

Last Quarter

+15 102 000 000 USD

Current Year

+39 430 000 000 USD

Last Year

+33 903 000 000 USD

Current Quarter

+11 199 000 000 USD

Last Quarter

+10 706 000 000 USD
EBITDA 27 366 000 640 USD
Operating Margin TTM 30.43 %
Price to Earnings 79.31
Return On Assets TTM 8.34 %
PEG Ratio 0.41
Return On Equity TTM 88.40 %
Wall Street Target Price 209.12 USD
Revenue TTM 57 366 999 040 USD
Book Value 0.80 USD
Revenue Per Share TTM
Dividend Share 6.38 USD
Quarterly Revenue Growth YOY 8.40 %
Dividend Yield 3.44 %
Gross Profit TTM 40 739 000 320 USD
Earnings per share 2.35 USD
Diluted Eps TTM 2.35 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -6.30 %
Profit Margin 7.31 %

Stock Valuation ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 79.31
Forward PE 15.77
Enterprise Value Revenue 7.03
Price Sales TTM 5.74
Enterprise Value EBITDA 27.19
Price Book MRQ 238.24

Technical Indicators ABBV

For 52 Weeks

159.42 USD 214.80 USD
50 Day MA 187.45 USD
Shares Short Prior Month 19 929 844
200 Day MA 188.16 USD
Short Ratio 2.50
Shares Short 14 700 538
Short Percent 0.83 %